GB9910119D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB9910119D0
GB9910119D0 GBGB9910119.8A GB9910119A GB9910119D0 GB 9910119 D0 GB9910119 D0 GB 9910119D0 GB 9910119 A GB9910119 A GB 9910119A GB 9910119 D0 GB9910119 D0 GB 9910119D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9910119.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB9910119.8A priority Critical patent/GB9910119D0/en
Publication of GB9910119D0 publication Critical patent/GB9910119D0/en
Priority to PCT/EP2000/003708 priority patent/WO2000066724A2/en
Priority to AU44025/00A priority patent/AU4402500A/en
Priority to EP00925239A priority patent/EP1181361A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
GBGB9910119.8A 1999-04-30 1999-04-30 Organic compounds Ceased GB9910119D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB9910119.8A GB9910119D0 (en) 1999-04-30 1999-04-30 Organic compounds
PCT/EP2000/003708 WO2000066724A2 (en) 1999-04-30 2000-04-26 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna
AU44025/00A AU4402500A (en) 1999-04-30 2000-04-26 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna
EP00925239A EP1181361A2 (en) 1999-04-30 2000-04-26 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9910119.8A GB9910119D0 (en) 1999-04-30 1999-04-30 Organic compounds

Publications (1)

Publication Number Publication Date
GB9910119D0 true GB9910119D0 (en) 1999-06-30

Family

ID=10852654

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9910119.8A Ceased GB9910119D0 (en) 1999-04-30 1999-04-30 Organic compounds

Country Status (4)

Country Link
EP (1) EP1181361A2 (en)
AU (1) AU4402500A (en)
GB (1) GB9910119D0 (en)
WO (1) WO2000066724A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2832154B1 (en) 2001-11-09 2007-03-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE
DE10258677A1 (en) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Combined use of antisense oligonucleotides for treating cancer, directed against the Polo-like kinase 1 and B cell leukemia/lymphoma 2 genes, having a synergistic effect
FR2852606A1 (en) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med In vitro method for simultaneous inhibition of several genes, useful for treating cancer or viral infection, using a ligand that binds to a common site in the genes and induces cutting by topoisomerase
CN112274641A (en) 2014-01-28 2021-01-29 巴克老龄化研究所 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470974A (en) * 1985-03-15 1995-11-28 Neu-Gene Development Group Uncharged polynucleotide-binding polymers
PT1584682E (en) * 1993-09-20 2009-08-03 Univ Pennsylvania Regulation of bcl-2 gene expression
WO1995031470A2 (en) * 1994-05-13 1995-11-23 Merck Frosst Canada Inc. Antisense inhibitors of gene expression
US5874566A (en) * 1996-10-25 1999-02-23 Hisamitsu Pharmaceutical Co. Inc. Il-15 triplex oligonucleotides
JP2002519048A (en) * 1998-07-02 2002-07-02 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Oligonucleotide inhibitors of bcl-xL
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
WO2000066724A2 (en) 2000-11-09
WO2000066724A3 (en) 2001-02-08
AU4402500A (en) 2000-11-17
EP1181361A2 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
GB9903759D0 (en) Organic compounds
GB9903547D0 (en) Organic compounds
GB9907097D0 (en) Organic compounds
GB9908533D0 (en) Organic compounds
GB9903548D0 (en) Organic compounds
GB9902938D0 (en) Organic compounds
GB9907908D0 (en) Organic compounds
GB9910119D0 (en) Organic compounds
GB9910965D0 (en) Organic compounds
GB9900293D0 (en) Organic compounds
GB9907822D0 (en) Organic compounds
GB9903669D0 (en) Organic compounds
GB9903754D0 (en) Organic compounds
GB9902939D0 (en) Organic compounds
GB9908468D0 (en) Organic compounds
GB9908531D0 (en) Organic compounds
GB9903667D0 (en) Organic compounds
GB9908532D0 (en) Organic compounds
GB9909333D0 (en) Organic compounds
GB9903546D0 (en) Organic compounds
GB9903755D0 (en) Organic compounds
GB9903545D0 (en) Organic compounds
GB9903757D0 (en) Organic compounds
GB9901939D0 (en) Organic compounds
GB9907823D0 (en) Organic compounds

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application
AT Applications terminated before publication under section 16(1)